INTRODUCTION {#s1}
============

Despite the development of various guidelines \[[@ref1],[@ref2],[@ref3]\], approaches to antifungal treatment in stem cell transplantation (SCT) centers differ according to country and even between centers. This inspired the development of another survey aimed at understanding the antifungal treatment policies of Turkish SCT centers.

MATERIALS AND METHODS {#s2}
=====================

Out of 28 EBMT-registered SCT centers, 26 responded to the survey ([Figure 1](#f1){ref-type="fig"}). The questionnaire consisted of separate sections defined to understand the basic treatment approach in each center as empirical or diagnostic-driven, the use of diagnostic tools to start or end a treatment, strategies in empirical or diagnostic-driven treatment, and the use of antifungal combinations.

RESULTS {#s3}
=======

Center Characteristics {#s3a}
----------------------

While 19 (73.1%) of these centers are adult SCT centers, 7 (26.9%) are pediatric SCT centers. While all centers (26) are performing allogeneic transplants, 24 centers are also performing autologous transplants. Among the 26 allogeneic centers, 24 are performing non-myeloablative, 7 non-related, and 6 cord blood cell transplants.

Treatment Approach {#s3b}
------------------

Four centers (16%) reported that they were only using empirical antifungal treatment, while 56% of the centers reported that they initially employ empirical treatment but that further treatment decisions are based on diagnostic tools such as high resolution computed tomography (HRCT) of the lungs and galactomannan (GM) ([Figure 2](#f1){ref-type="fig"}). Twenty percent of the centers reported that they always use a diagnostic-driven approach and 8% of the centers stated that they use an empirical approach in selected cases.

Salvage Therapy {#s3c}
---------------

In non-responding patients, 70% of the centers stop the initial antifungal treatment and switch to another class of antifungal. Twenty-five percent of the centers reported that they add another antifungal to the initial treatment.

Drug Selection {#s3d}
--------------

In empirical approaches, the first drug is amphotericin-B (conventional in 6/21 centers, liposomal in 6/21 centers) in the allogeneic setting ([Figure 3](#f2){ref-type="fig"}). This is followed by voriconazole (4/21) and caspofungin (2/21). This trend is similar in the autologous setting, but voriconazole is less commonly used in autologous transplants. Voriconazole is the main choice in proven cases in allogeneic (23/25) and in autologous (21/23) transplants.

In centers treating their patients based on HRCT and GM (diagnostic-driven treatment), the main drug of choice is voriconazole (15/20), followed by amphotericin-B (5/20), in the allogeneic setting. This trend is similar in other transplant settings.

When using antifungal combination therapy, 57% of the centers add voriconazole to initial amphotericin-B treatment, while 38% add caspofungin to initial amphotericin-B and 5% use voriconazole with caspofungin ([Figure 4](#f3){ref-type="fig"}).

End of Treatment {#s3e}
----------------

It was found that 33.3% of the centers continue the antifungal treatment until the end of neutropenia in empirical treatment. Other centers reported that they use both resolution of neutropenia and other evidence such as the clinical condition, diagnostic tools, presence of graft-versus-host disease (GVHD), and pre-transplant fungal status to decide to stop the treatment.

In diagnostic-driven approaches, treatment mainly stops at 90 days (23.8%), after radiological improvement (19%), or after resolution of neutropenia (14.3%).

Most of the centers continue oral antifungals, especially in patients with partial radiological resolution and GVHD.

Patient Selection {#s3f}
-----------------

Diagnostic-driven treatment is mainly used in allogeneic settings (19/26 in allogeneic transplants, 18/24 in nonmyeloablative transplants), with a rate of 62.5% (15/24) in autologous settings.

Candida Treatment {#s3g}
-----------------

Echinocandin is the first drug of choice in established Candida infections at 17/25 centers in allogeneic and 17/23 centers in autologous transplants, followed by amphotericin-B (5/25) in allogeneic and fluconazole in autologous settings.

Further Treatment {#s3h}
-----------------

In patients not responding to initial antifungal treatment, 70% of the centers stop the initial antifungal and start a new one, and 25% of the centers choose to use a combination antifungal treatment.

Diagnostic Tools {#s3i}
----------------

HRCT is routine in 23/26 centers, GM is routine in 4/26 centers, and beta-glucan and molecular diagnosis are routine in 4/26 centers.

General Approach {#s3j}
----------------

When asked about their view on empirical or diagnostic-driven approaches in patients with prolonged fever and neutropenia, 46.2% responded in favor of empirical treatment and 11.5% in favor of a diagnostic-driven approach, while 42.3% responded that the choice should be made per patient and most of them choose to use empirical treatment in high-risk patients ([Figure 2](#f1){ref-type="fig"}).

DISCUSSION AND CONCLUSION {#s4}
=========================

Although there has been an increasing trend towards the use of diagnostic-based treatments in Turkey in the last few years, empirical treatment is still the main approach. HRCT is the major determinant of diagnostic-driven treatment, and while amphotericin-B is the main drug in empirical treatment, voriconazole is the main choice in diagnostic-driven treatment and proven cases. Despite the guidelines, a large number of centers are using antifungal drug combinations. Keeping in mind that there is still controversy about the selection of empirical therapy versus preemptive (diagnostic-driven) therapy, the differences between the centers in this aspect is understandable. The frequent use of antifungal combinations is interesting, but especially in centers with inadequate diagnostic tools, this approach is to be expected, especially when physicians are faced with a fungal infection that may end up having dreadful consequences.
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